Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | GAA | P10253 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | AOC2 | O75106 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30147703 | 0.82 | KDM4E (0.41) | ALDH1A1GAAKDM4EKMT2AMAPT | |
| SCHEMBL9102928 | 0.79 | BAZ2B (0.39) | ALDH1A1KDM4EKMT2AMAPTCYP1A2 | |
| SCHEMBL31183044 | 0.79 | PTGS2 (0.35) | ALDH1A1GAAKDM4EKMT2AMAPT | |
| SCHEMBL28070421 | 0.78 | BAZ2B (0.38) | ALDH1A1KDM4EKMT2AMAPTCYP1A2 | |
| SCHEMBL16973593 | 0.77 | FNTA (0.41) | ALDH1A1GAAKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1646369 | 0.76 | L3MBTL1 (0.35) | ALDH1A1KDM4EKMT2AMAPTCYP1A2 | |
| SCHEMBL25515640 | 0.75 | MAPT (0.48) | ALDH1A1GAAKDM4EKMT2AMAPT | |
| SCHEMBL6248007 | 0.75 | L3MBTL1 (0.40) | ALDH1A1GAAKDM4EKMT2AMAPT | |
| SCHEMBL25515348 | 0.75 | PTPN1 (0.42) | ALDH1A1GAAKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL25515352 | 0.75 | MAPT (0.36) | ALDH1A1GAAKDM4EKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1011670-A4 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | LILLY CO ELI (US) | 2004-10-27 | — | — | EP | claimed |
| US-6645976-B1 | Nonpancreatic secretory phospholipase (sPLA2) supressors such as 2-(3-Benzyl-8-hydroxy-2-ethylindolizin-1-yl)acetamide, administered to control release of fatty acid and prevent the arachidonic acid cascade; septic shock | ELI LILLY AND COMPANY | 2003-11-11 | — | — | US | claimed |
| EP-0772596-B1 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 2003-10-01 | — | — | EP | claimed |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | ELI LILLY AND COMPANY | 2003-06-26 | — | — | US | claimed |
| EP-1011670-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 2000-06-28 | — | — | EP | claimed |
| EP-1007056-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 2000-06-14 | — | — | EP | claimed |
| WO-1999016453-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | claimed |
| EP-0772596-A4 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 1999-01-13 | — | — | EP | claimed |
| CN-1158121-A | Indolizine sPLA2Inhibitors | LILLY CO ELI (US) | 1997-08-27 | — | — | CN | claimed |
| EP-0772596-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-14 | — | — | EP | claimed |
| WO-1996003383-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | claimed |
| EP-1011670-A4 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | LILLY CO ELI (US) | 2004-10-27 | — | — | EP | disclosed |
| US-6645976-B1 | Nonpancreatic secretory phospholipase (sPLA2) supressors such as 2-(3-Benzyl-8-hydroxy-2-ethylindolizin-1-yl)acetamide, administered to control release of fatty acid and prevent the arachidonic acid cascade; septic shock | ELI LILLY AND COMPANY | 2003-11-11 | — | — | US | disclosed |
| EP-0772596-B1 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 2003-10-01 | — | — | EP | disclosed |
| US-6610728-B2 | SPLA2 inhibitor, secretory phospholiase A2 inhibitors 1H-indole-3-glyoxylamide compound or a pharmaceutically acceptable salt, solvate, or a prodrug | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0772596-A4 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 1999-01-13 | — | — | EP | disclosed |
| EP-0772596-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003383-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | TPP2, PLAAT2, PLAA | ALDH1A1 1230/4885GAA 685/4885KDM4E 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.